Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Multicenter, Phase 2 Study of Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

NCT03410108 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT03410108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03410108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Multicenter, Phase 2 Study of Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Completed
Start date
January 29, 2018
Completion date
July 28, 2021
Enrollment
104 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

alk-positive advanced nsclc